Where new rules meet scarce oversight, a recurring market for evidence emerges. The thesis separates approved capacity from mere equipment exposure.
Everyone is looking for the best way to play the massive wave of global supply-chain duplication and reshoring. This analysis examines why the market’s current favourite answer—buying the companies that supply physical equipment and consumables to these new factories—fundamentally misprices the real bottleneck of the late 2020s. The true scarcity is no longer the physical capacity to build; it is the legal right to operate.
9–15x Operating Earnings
The market currently misprices major testing and certification groups as cyclical industrial consultants. Historically, these businesses command multiples between 15x and 20x. The upside here is driven by a structural reclassification—the market recognizing them as highly resilient compliance annuities—rather than chasing unrealistic, software-like margins.
31 December 2030
The legally binding deadline for the European Train Control System (ERTMS) to be fully operational across core rail corridors. With only 10–15% of the network currently equipped, this represents the single hardest regulatory cliff—and the clearest investment catalyst for integrators—in this entire analysis.
29 September 2026
The critical enforcement deadline where certain pharmaceutical tariffs default to 100% for companies lacking pre-cleared onshoring agreements. Whether regulators strictly enforce this—or cave to mass exemptions—will prove whether the promised wave of duplicated factory builds is economically real or just political theater.
The following overview summarizes the strategic building blocks, position directions, and allocated assets for this research theme.
These are the companies that governments deputise to enforce their rules. They collect more mandates as regulatory requirements expand and gain delegated inspection work when the state must outsource its backlog.
These specialised engineers validate new facilities. The credential, rather than the wage, is the barrier to entry, but the businesses are currently priced as standard cyclical staffing consultancies.
EU rail signalling faces a legally binding core-network deadline of 31 December 2030, protected by a strict certification firewall. The underlying companies trade at modest valuations without a thematic premium.
This is an opportunistic position rather than a core holding. Buy only on price dips, preferring essential filtration and media over chromatography resins.
This is a source of funds for the rest of the portfolio. The 2027–29 capacity wave is real, but rising Asian competition may weaken cash quality before passive thematic ownership reacts.
Fragmentation is no longer just a temporary political phase; it is hardening into permanent administrative infrastructure. But the binding constraint has migrated. Duplicated plants, power grids and rail corridors are being built, but the governments that mandated them cannot inspect, certify or verify them fast enough.
Through the early 2030s, the global economy will run a queue. Inspection slots, validated engineering headcount and accredited laboratory capacity are strictly rationed. The political resolution to this backlog is to deputise.
An entire permanent industry is hardening around attesting to attributes rather than manufacturing physical goods: verifying carbon content through CBAM, material origin, recycled content, digital product passports through ESPR, and cybersecurity conformity. These services are priced per site, per tonne or per product line. They are indexed to regulatory ratchets, funded entirely outside government budgets, and are largely immune to broader economic cycles.
Critics argue that the core TIC trade is too slow. Policy sparks are priced in immediately on announcement; by the time the steady accumulation of mandates is obvious to everyone, the easy money has been made.
Response: We are intentionally swapping the hope of a speculative triple-digit return for a highly probable, steady compounder. That is investment discipline, not a flaw.
The same policy that gives these testing companies more volume also opens the door to cheaper, third-country certifiers being recognised by Western governments. If price competition arrives faster than the number of mandates grows, these companies could be trapped as low-margin volume businesses forever.
Regulatory compliance has no flashy sector tag, no clean stock screener and no dedicated ETF plumbing. You can be entirely right about the economics and still see the stock move slowly because passive money is not forced to buy it. Grid equipment, owned broadly as an “AI data-centre” proxy, can keep rising on blind thematic momentum.
Will the EU’s current push to cut red tape thin out upcoming regulations such as digital product passports and deforestation rules? If so, the core thesis loses some of its fuel.
Will the legally binding 2030 deadline for European rail signalling survive? If governments divert infrastructure funds to other pressing needs, this mandate could be delayed, converting a sharp, profitable regulatory cliff into a sluggish, ordinary industrial cycle.
| Rank | Layer | Rationale |
|---|---|---|
| 1 | I. Adjudicators and Deputies (The Core) | Testing, Inspection and Certification groups, notified regulatory bodies and software registries that host digital product passports collect many small, mandatory payments. The revenue adjusts for inflation, does not depend heavily on economic booms, and is built on thousands of compliance checks. The market currently values these companies at roughly 9–15× operating earnings, often mistaking them for standard consulting firms. As regulations stack up, the valuation could climb toward 16–20× earnings. |
| 2 | II. Certified Human Capital and Validation Services | Specialised validation engineers, nuclear quality-assurance staff and certified high-voltage technicians hold the most mispriced layer. These businesses are valued at 8–12× earnings as if they were temporary staffing agencies, although their credentials and experience create a monopoly on bottleneck capacity. The strongest companies are private, so listed exposure must be bought selectively. |
| 3 | III. Holders of Live Certificates | Facilities that already hold the legal approvals to operate, such as sterile pharmaceutical plants, approved nuclear-component manufacturers and licensed aviation-maintenance hubs, enjoy a five-to-eight-year scarcity premium. New competitors remain in the regulatory waiting room, but this advantage will fade as regulators clear the backlog. |
| 4 | IV. Per-Batch Consumables | Bioprocessing media, filters and single-use manufacturing volumes are widely loved by the market but structurally challenged. Growth is capped by the speed at which regulators approve new factories, while process intensification can reduce the raw materials required for the same product output. |
The durable economics sit with accepted proof, certified capacity and dated technical obligations. Equipment manufacturers remain exposed to rising competition once the physical capacity wave catches up with demand.
The selection below is organised by economic role. Leeway ratings describe each company independently of this research topic; they are not a substitute for the arguments on this page.
The Business-Rating scores the quality of the business model, independent of the share price. The Market-Fit-Rating tests eighteen fundamental figures for how well the company currently fits the market; a negative reading implies expected negative performance. The Cycle-Rating places the valuation in the stock’s own history: a higher figure means the shares are historically cheaper. The Leeway-Score combines the three in equal parts. How the ratings are calculated
From 19 August 2026 to 19 October 2026: Portfolio-2.2%ACWI-1.6%
These are the companies that governments deputise to enforce their rules. They collect more mandates as regulatory requirements expand and gain delegated inspection work when the state must outsource its backlog.
Role in thesis: Provides the broadest exposure to the growing sum of compliance duties, including origin and content attestation, carbon verification, product conformity, and drug manufacturing audits.
Valuation context: Each individual duty is small, but the aggregate volume grows with every new regulation. Pricing is typically linked to inflation, offering a steady, compounding revenue base.
Invalidation risk: Operating margins are structurally capped near 20%. A Swiss franc cost base and a history of heavy acquisitions make organic growth difficult to parse. The market re-rating will likely be gradual rather than immediate.
Role in thesis: A testing group with the cleanest focus on infrastructure, marine classification, and building and energy certification.
Valuation context: A ship’s classification is a legal prerequisite for its operation. This exact logic is now being applied to carbon border levies, construction, and offshore assets, providing recurring, mandate-driven revenue without requiring software-like valuations.
Invalidation risk: Shipping and industrial capital spending are inherently cyclical. The company’s growth relies partly on acquisitions, and margins face the same structural ceiling as its peers. Any failed M&A activity would likely pressure the share price.
Role in thesis: A high-margin testing group heavily geared toward the conformity and certification of individual products.
Valuation context: Emerging eco-design regulations are shifting compliance from a one-off type approval into recurring, per-batch testing. This creates a new and durable stream of recurring income that aligns closely with Intertek’s core business.
Invalidation risk: A substantial portion of revenue is tied to consumer goods, making it vulnerable to consumer spending cycles. The valuation discount associated with its London listing may persist indefinitely, and product passport revenues will remain a small part of the total base for years.
Role in thesis: An extensive accredited laboratory network covering food, environment, drug testing, and clinical work.
Valuation context: Currently the most attractively priced large company in the testing and certification space. Testing for PFAS chemicals and food safety drives volume independently of the broader macroeconomic cycle.
Invalidation risk: The primary risks are governance-related rather than operational. Founder control, family-owned laboratory properties, complex reporting, and heavy acquisition accounting mean minority shareholders are not always the priority. Position sizing should reflect this risk.
Long
Role in thesis: Safety-certification gatekeeper for electrical equipment, batteries, energy storage and renewable hardware.
Valuation context: The UL mark is effectively a prerequisite for market access in North America and increasingly elsewhere. UL Solutions therefore earns from the electrification build-out without carrying the manufacturers' capacity cycle or pricing risk. The value lies in the certification mandate, not in a technology premium.
Invalidation risk: The shares have already re-rated partly since the 2024 listing, so the entry-price argument is weaker here. A release of shares from the founding trust, US revenue concentration and competition between certification providers remain risks. The thesis is invalidated if the mark loses its practical market-access force or pricing no longer covers the credentialed cost base.
Long
Role in thesis: Accredited laboratory exposure across life sciences, environmental, food and minerals testing, with an Australian listing outside the crowded European testing screen.
Valuation context: Environmental and PFAS testing are regulatory obligations with per-sample economics, while life-science testing adds a less cyclical source of demand. ALS captures the same adjudication and proof requirement through a different geography and investor base.
Invalidation risk: The minerals division links a meaningful share of earnings to exploration cycles and gold prices, while Australian-dollar exposure adds another variable. The commodity cycle has already helped the valuation. The thesis is invalidated if mandated testing growth fails to offset minerals cyclicality or if margins no longer compensate for the laboratory cost base.
Role in thesis: China’s largest independent provider of testing, inspection, and certification services.
Valuation context: Regulatory fragmentation is a global trend. China is building its own mandatory certification, carbon accounting, and food safety frameworks. As a domestic accredited laboratory, CTI captures this work without needing to compete for Western accreditations.
Invalidation risk: Domestic price competition in the Chinese testing market is severe and has compressed margins. Restricted access to A-shares, lower disclosure standards, and two-way geopolitical policy risks mean this should be sized as a small, diversifying position.
Role in thesis: Serialisation, track-and-trace and inspection infrastructure for proving what a medicine or food product is and where it came from.
Valuation context: This is a direct listed expression of per-product attestation. Pharmaceutical serialisation, food traceability and digital product passports turn regulatory proof into a recurring technology requirement, while the market has largely abandoned the company after its execution failures.
Invalidation risk: The company is small, thinly traded and carries a difficult margin, balance-sheet and governance history. Customers can defer capex, and the investment case is exposed to execution more than the larger testing groups. The thesis is invalidated if product-passport and serialisation mandates are delayed or if the evidence layer becomes a low-margin commodity.
Role in thesis: A provider of non-destructive testing for critical infrastructure, including pipelines, refineries, bridges, and aerospace structures.
Valuation context: These inspections are legally mandated on strict schedules, regardless of whether the customer is actively investing in new capital projects. The business is constrained by the availability of certified inspectors, not by end-market demand.
Invalidation risk: The company carries high leverage, thin margins, heavy dependence on oil and gas customers, and struggles with the imperfect pass-through of rising wages. The stock has been cheap for a decade and requires a clear operational catalyst to re-rate.
Role in thesis: A supplier of metrology equipment and assured positioning and timing systems.
Valuation context: Regulatory conformity must be precisely measured. Hexagon supplies the necessary measurement equipment across manufacturing and construction, while its navigation segment provides a resilient backup option in the event of satellite outages.
Invalidation risk: The company is a complex software and industrial hybrid with an acquisition-heavy history and opaque segment reporting. Automotive and construction end-markets are cyclical, and ongoing corporate separation plans carry execution risk.
Look behind the scenes: see not only what we buy, but why. Get the complete view of our strategy.
| When | What happens | Why it matters |
|---|---|---|
| 29 September 2026 | 29 September 2026: Certain pharmaceutical tariffs default to 100% for companies outside pre-cleared agreements. | Whether governments enforce this tariff or grant mass exemptions is the ultimate test of whether the mandated factory duplication is real. |
| 1 January 2027 | TIC organic growth is split into price and volume. | This metric will show whether regulatory accreditation is a highly profitable moat or merely a commoditised service. |
| 1 January 2027 | CBAM and ESPR rollouts begin to create operational obligations, including digital battery passports from 2027. | Each specific legal act matters more than the headline political promise. |
| deputisedState.calendar.open | Grid equipment exit triggers: large-transformer lead times shorten towards 24 months, tender prices flatten, or customer advance payments roll over. | Two of these three signals are required before fully exiting grid equipment. |
| Path | Weight | What happens |
|---|---|---|
| Bull Case (22%) — The mandate stack gets a name | 22% | Digital passports, carbon tariffs and strict manufacturing obligations land exactly on schedule. Rail signalling contracts surge with fresh infrastructure funding. The broader market recognises testing and certification companies as high-margin compliance annuities, and the core layer re-rates aggressively. |
| Base Case (45%) — A steady grind upward for the core, while grid equipment deflates on schedule | 45% | The number of mandates compounds unevenly. Testing and certification laboratories repair their valuations over three to five years and deliver low-to-mid-teens annualised returns. Rail signalling rises as deadlines approach, while grid equipment valuations compress by 2029 as new global capacity arrives. |
| Bear Case (23%) — Fiscal exhaustion and deregulation cut both ways | 23% | The EU cuts upcoming product-passport and environmental regulations. A new US administration unwinds pharmaceutical tariff pressure, pledged factory construction halves, cheaper foreign certifiers flood the market, and rail signalling deadlines are formally delayed. The portfolio’s limited downside from buying companies that are already cheap becomes the main protection. |
| Anti-Thesis (10%) — The spark fires in the layer we demoted | 10% | Governments solve inspection backlogs by recognising foreign approvals. Duplicated factories are approved on time, and pharmaceutical consumables accelerate in 2027 rather than 2029. Picks-and-shovels stocks rise rapidly while the regulatory layer moves sideways, and grid-equipment firewalls prove harder to breach than modelled. |
The assessment is produced in several steps. Independent model families answer the same question separately and then attack the results. What you read here has survived several rounds.
Any analysis can be wrong. That is why the falsification criteria and the counter-position sit on the same page as the thesis, not in the small print.
The numbers shown against individual companies do not come from this process. The Business-Rating scores business-model quality, the Market-Fit-Rating eighteen fundamental figures against the current market, the Cycle-Rating the valuation against the stock’s own history. They are documented under the Leeway scores.
Leeway rates business quality, fundamental market fit and valuation timing separately. Use the company cards to test the portfolio logic against individual businesses, then read how the ratings are built.
The data is recalculated on a weekly basis and depends on the current market value of the company and the balance sheet figures of the annual financial statements. The market value changes continuously with price changes, the balance sheets are created annually and change the valuation massively. The time of the annual financial statements and the metrics used can be viewed under "Metrics". Further information on how the analyses work can be found as tooltips directly on the analyses as well as in our explanations.
The information is intended to support you in your independent decision-making in implementing investment strategies and serves purely informational purposes. Past performance is not a reliable indication of future performance. No warranty can be given for the completeness, correctness and accuracy of the listed content. The information does not constitute specific investment recommendations. We neither know you nor your financial situation and do not provide investment advice. Only licensed investment advisors with knowledge of your personal circumstances may do this. PWP Leeway UG (limited liability) is not an investment advisor and does not collect any personal data for the purpose of investment optimization. PWP Leeway UG (limited liability) is a provider of investment recommendations and investment strategy recommendations. As such, it is registered with and supervised by the Federal Financial Supervisory Authority (BaFin). The legal notices on the use of the website and the General Terms and Conditions of PWP Leeway UG (limited liability) also apply.
All price data are closing prices of the respective stock exchanges. Price information and master data are provided by an external service provider. Furthermore, public trading data, such as provided by Finra.org, is used to analyze market behavior. No warranty can be given for the completeness, correctness and accuracy of the listed content.
Disclosure of interests: To the best of our knowledge, Leeway and the persons responsible for creating or publishing the respective content do not hold a net long or net short position exceeding 0.5% of the issued share capital of any issuer discussed in that content at the time of publication. There are no other interests or business relationships that could conflict with objectivity, unless expressly stated otherwise in the respective content.
